MorphoSys AG sell mohabbatein
Summary
This prediction ended on 13.02.19 with a price of €97.50. With a performance of -6.07%, the SELL prediction for MorphoSys AG by mohabbatein was down slightly. mohabbatein has 50% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
MorphoSys AG | 0.444% | 0.444% | 128.991% | 23.904% |
iShares Core DAX® | 0.039% | 0.567% | 12.281% | 14.748% |
iShares Nasdaq 100 | -4.018% | -5.554% | 23.851% | 36.769% |
iShares Nikkei 225® | -2.389% | -1.434% | 8.335% | 5.073% |
iShares S&P 500 | -2.115% | -2.351% | 22.061% | 37.971% |
Comments by mohabbatein for this prediction
In the thread Morphosys AG diskutieren
Deckel bei 103 Euro?
Da steckt derzeit viel Optimismus drin. Aber bei rund 103/104 Euro scheint ein Deckel drauf zu sein. Und mit den nächsten Marktturbulenzen kann es ganz schnell wieder abwärts gehen. Die Firma bleibt interessant, aber eben auch hoch bewertet. Und jeglicher Rückschlag in der Medikamentenpipeline könnte als willkommener Anlass zum Verkauf genutzt werden.
SELL.